97% of Surveyed Injection Users Would Consider Pump Therapy - if Easier to Learn and Improved Outcomes
Conducting Additional Research Initiative in Conjunction with Commercialization of the Pivot Tubeless Insulin Patch Pump
Company to Showcase Pivot at Association of Diabetes Care & Education Specialists (ADCES) Annual Conference, August 7-10, 2026
SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology, today announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026.
Research Reveals Strong Interest in Simple, Outcome-Improving Pump Therapy
Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology:
97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options.
Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually.
55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.